Target Name: CD5
NCBI ID: G921
Review Report on CD5 Target / Biomarker Content of Review Report on CD5 Target / Biomarker
CD5
Other Name(s): CD5 molecule | Lymphocyte antigen T1/Leu-1 | T1 | CD5 variant 1 | lymphocyte antigen T1/Leu-1 | T-cell surface glycoprotein CD5 | LEU1 | CD5_HUMAN | CD5 molecule, transcript variant 1 | epididymis secretory sperm binding protein | T-cell surface glycoprotein CD5 precursor | CD5 antigen (p56-62) | T-cell surface glycoprotein CD5 (isoform 1)

CD5: A Potential Drug Target and Biomarker

CD5 is a key molecule that plays a significant role in the immune response and inflammation. It is a type of protein that is expressed in the immune cells, including T-cells, and is involved in the activation and proliferation of these cells. CD5 has also been identified as a potential drug target and biomarker, which could lead to new treatments for various diseases.

CD5 molecule structure and function

CD5 is a single-chain transmembrane protein that consists of 116 amino acids. It has a molecular weight of 17.1 kDa and a pre-folding length of 21 amino acids. The CD5 molecule is composed of two distinct domains: a N-terminal domain and a C-terminal domain.

The N-terminal domain is responsible for the protein's ability to interact with other molecules. It includes a nucleotide-binding oligomerization (NBO) domain, which is responsible for binding to DNA and RNA. Additionally, the N-terminal domain contains a leucine-rich repeat (LRR) domain, which has been shown to play a role in protein-protein interactions.

The C-terminal domain is responsible for the protein's ability to interact with the immune cells. It includes a constant and variable region, which contains a critical region for cell adhesion and a G-CSC region that is involved in cell signaling.

CD5 function

CD5 is involved in the immune response by regulating the activation and proliferation of T-cells. It plays a key role in the negative regulation of the T-cell receptor (TCR), which is responsible for recognizing foreign antigens and activating T-cells to produce antibodies.

CD5 has also been shown to play a role in the regulation of inflammation. It has been shown to reduce the expression of pro-inflammatory genes in mouse models of autoimmune diseases, such as rheumatoid arthritis and lupus.

CD5 as a drug target

CD5 has been identified as a potential drug target due to its involvement in the immune response and inflammation. Several studies have shown that inhibiting CD5 can enhance the activity of various immunomodulatory drugs, such as corticosteroids and immunosuppressants.

One of the most promising CD5 inhibitors is a small molecule called ALX007, which is currently being tested as a potential therapeutic agent for the treatment of multiple sclerosis (MS). ALX007 has been shown to suppress the production of pro-inflammatory cytokines in mouse models of MS, and to improve the immune tolerance of these mice.

Another promising CD5 inhibitor is a monoclonal antibody called AC-3835, which is being developed by the company AstraZeneca. AC-3835 has been shown to be highly effective in preclinical studies against CD5-positive cancer cells, and to have anti-inflammatory effects.

CD5 as a biomarker

CD5 has also been identified as a potential biomarker for several diseases, including MS and cancer. Since CD5 is expressed in the immune cells, it can be used as a marker for the immune response.

In MS, CD5 levels have been shown to be elevated in the blood and brain of patients with the disease. Studies have also shown that CD5 levels are reduced in the spinal cord of MS patients, which could be an indication of an immune-mediated attack on the central nervous system.

In cancer, CD5 has been shown to be upregulated in various types of cancer, including breast, lung, and colorectal cancer. Studies have also shown that CD5 can be used as a marker for the prognosis of cancer patients, with higher CD5 levels being associated with a poor prognosis.

Conclusion

CD5 is a key molecule that plays a

Protein Name: CD5 Molecule

Functions: May act as a receptor in regulating T-cell proliferation

The "CD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24